论文部分内容阅读
近30年来,不少临床医师一直在寻找经静脉补充营养的方法,期望用这种支持疗法来治疗一些以往很难或无法治疗的危重病人。临床上作为氮源而用于输液的多为蛋白水解物,蛋白水解物虽可供给肌体营养成分和保持氮的平衡,但不可能大量及长期使用,更不能适应多种疾病对氨基酸成分的需要。而且蛋白质水解物的最主要缺点是含有肽类物质,其在临床上容易引起发热,恶心、呕吐、食欲不振和过敏等不良付反应。蛋白质水解物产品的稳定性也存在许多问题。鉴于上述种种原因,研究和生产氨基酸输液以弥补蛋白质水解液不足之处引起世界各国的普遍重视。目前,日本、德国、美国、瑞典、法国等国家均有氨基酸商品的生产和销售,品种及产量发展之快,实为惊人
For nearly 30 years, many clinicians have been looking for ways to supplement nutrition with intravenous fluids. They are expected to use this supportive therapy to treat some critically ill or untreatable critically ill patients in the past. Clinically as a source of nitrogen for transfusion are mostly protein hydrolysates, protein hydrolysates can supply nutrients to the body and maintain the balance of nitrogen, but not for large and long-term use, but also can not meet the needs of a variety of diseases, amino acid composition . And protein hydrolyzate’s main drawback is the inclusion of peptides, which are clinically prone to fever, nausea, vomiting, loss of appetite and allergies and other adverse reactions. There are also many problems with the stability of protein hydrolyzate products. In view of the above reasons, research and production of amino acid infusion to make up for the inadequacies of protein hydrolyzate caused universal attention of all countries in the world. At present, Japan, Germany, the United States, Sweden, France and other countries have the production and sale of amino acid products, the rapid development of varieties and yields, in fact, amazing